Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

Autor: S. Budd Haeberlein, P.S. Aisen, F. Barkhof, S. Chalkias, T. Chen, S. Cohen, G. Dent, O. Hansson, K. Harrison, C. von Hehn, T. Iwatsubo, C. Mallinckrodt, C.J. Mummery, K.K. Muralidharan, I. Nestorov, L. Nisenbaum, R. Rajagovindan, L. Skordos, Y. Tian, C.H. van Dyck, B. Vellas, S. Wu, Y. Zhu, A. Sandrock

Publikováno v: Journal of Prevention of Alzheimer's Disease, 9(2), 197-210. Springer International Publishing AG
Budd Haeberlein, S, Aisen, P S, Barkhof, F, Chalkias, S, Chen, T, Cohen, S, Dent, G, Hansson, O, Harrison, K, von Hehn, C, Iwatsubo, T, Mallinckrodt, C, Mummery, C J, Muralidharan, K K, Nestorov, I, Nisenbaum, L, Rajagovindan, R, Skordos, L, Tian, Y, van Dyck, C H, Vellas, B, Wu, S, Zhu, Y & Sandrock, A 2022, ' Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease ', Journal of Prevention of Alzheimer's Disease, vol. 9, no. 2, pp. 197-210 . https://doi.org/10.14283/jpad.2022.30

Background: Alzheimer’s disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25356f937683da76b27d9eec33c332a0
https://research.vumc.nl/en/publications/104cb695-ffcb-4502-aba8-9ab998dcbd40

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An Exploratory Dose-Escalating Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Atacicept in Patients with Systemic Lupus Erythematosus

Autor: V Yakusevich, C Pena-Rossi, J Hill, H Saunders, M Stanislav, I Nestorov, E Nasonov, O Ershova, N Lomareva

Publikováno v: Lupus

Atacicept, a recombinant fusion protein containing the extracellular, ligand-binding portion of the transmembrane activator and calcium modulator and cyclophilin-ligand interactor receptor, and the Fc portion of human immunoglobulin (Ig) G, is design

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9580394f792fd43c74c849182d7efcb
http://europepmc.org/articles/PMC3835146

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.